This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.
3 additional tumor biopsies
3 additional blood draws
Participants must have biopsiable non-target disease amenable to at least 3 biopsies.
None
John Kirkwood
Lead sponsor
University of Pittsburgh
Sponsor institution
Regeneron Pharmaceuticals
Collaborator